• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.耐氟喹诺酮艰难梭菌PCR-027中的gyrA突变
Emerg Infect Dis. 2007 Mar;13(3):504-5. doi: 10.3201/eid1303.060771.
2
Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.加拿大艰难梭菌临床分离株中莫西沙星耐药的分子特征。
Diagn Microbiol Infect Dis. 2010 Apr;66(4):419-24. doi: 10.1016/j.diagmicrobio.2009.12.002.
3
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.与毒素A阴性、毒素B阳性艰难梭菌gyrB基因新突变相关的对莫西沙星和加替沙星的高水平耐药性。
J Antimicrob Chemother. 2006 Dec;58(6):1264-7. doi: 10.1093/jac/dkl398. Epub 2006 Oct 3.
4
The characteristics of Clostridium difficile ST81, a new PCR ribotype of toxin A- B+ strain with high-level fluoroquinolones resistance and higher sporulation ability than ST37/PCR ribotype 017.艰难梭菌 ST81 的特征，一种新型的毒素 A-B+菌株的 PCR 核糖型，对氟喹诺酮类药物具有高水平耐药性，且比 ST37/PCR 核糖型 017 具有更高的孢子形成能力。
FEMS Microbiol Lett. 2018 Sep 1;365(17). doi: 10.1093/femsle/fny168.
5
Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.欧洲艰难梭菌感染前瞻性研究中艰难梭菌分离株对氟喹诺酮的耐药性
J Med Microbiol. 2008 Jun;57(Pt 6):784-789. doi: 10.1099/jmm.0.47738-0.
6
Antimicrobial susceptibility of Clostridium difficile isolates from ICU colonized patients revealed alert to ST-37 (RT 017) isolates.来自重症监护病房（ICU）定植患者的艰难梭菌分离株的药敏试验显示，对ST-37（RT 017）分离株需予以警惕。
Diagn Microbiol Infect Dis. 2017 Oct;89(2):161-163. doi: 10.1016/j.diagmicrobio.2017.06.021. Epub 2017 Jul 1.
7
PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates.爱尔兰临床艰难梭菌分离株中 PCR 核糖体分型流行情况以及大环内酯-林可酰胺-链阳性菌素 B（MLSB）和氟喹诺酮耐药的分子基础。
J Antimicrob Chemother. 2011 Sep;66(9):1976-82. doi: 10.1093/jac/dkr275. Epub 2011 Jun 27.
8
Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR.实时 PCR 检测艰难梭菌分离株中的 gyrA 和 gyrB 突变。
Mol Cell Probes. 2010 Apr;24(2):61-7. doi: 10.1016/j.mcp.2009.10.002. Epub 2009 Oct 21.
9
The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).基因内和基因外补偿性突变在鼠伤寒沙门氏菌gyrA突变体（D87G）中氟喹诺酮耐药性抑制中的作用
J Antimicrob Chemother. 2009 Feb;63(2):290-4. doi: 10.1093/jac/dkn480. Epub 2008 Nov 24.
10
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.产毒艰难梭菌分离株对莫西沙星的耐药性与gyrA基因突变有关。
Antimicrob Agents Chemother. 2001 Aug;45(8):2348-53. doi: 10.1128/AAC.45.8.2348-2353.2001.

引用本文的文献

1
Allele-linked divergence in SlpA and TcdB drives distinct immune and cytotoxic responses that distinguish ST01 from non-ST01 strains in Clade 2 Clostridioides difficile.SlpA和TcdB中的等位基因连锁差异驱动了不同的免疫和细胞毒性反应，这些反应区分了2型艰难梭菌中的ST01菌株与非ST01菌株。
Access Microbiol. 2025 Sep 10;7(9). doi: 10.1099/acmi.0.000994.v3. eCollection 2025.
2
Antibiotic Resistances of Clostridioides difficile.艰难梭菌的抗生素耐药性。
Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9.
3
Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes.艰难梭菌 106 型菌株的系统基因组分析揭示了新的遗传岛和新兴表型。
Sci Rep. 2020 Dec 17;10(1):22135. doi: 10.1038/s41598-020-79123-2.
4
How Oxygen Availability Affects the Antimicrobial Efficacy of Host Defense Peptides: Lessons Learned from Studying the Copper-Binding Peptides Piscidins 1 and 3.氧可用性如何影响宿主防御肽的抗菌功效：从研究铜结合肽鱼抗菌肽 1 和 3 中学到的经验教训。
Int J Mol Sci. 2019 Oct 24;20(21):5289. doi: 10.3390/ijms20215289.
5
Proteotyping of as Alternate Typing Method to Ribotyping Is Able to Distinguish the Ribotypes RT027 and RT176 From Other Ribotypes.将蛋白质分型作为核糖体分型的替代分型方法能够区分核糖体分型RT027和RT176与其他核糖体分型。
Front Microbiol. 2019 Sep 10;10:2087. doi: 10.3389/fmicb.2019.02087. eCollection 2019.
6
Whole genome analysis reveals new insights into the molecular characteristics of NAP1/BI/027/ST1 clinical isolates in the People's Republic of China.全基因组分析揭示了中国NAP1/BI/027/ST1临床分离株分子特征的新见解。
Infect Drug Resist. 2019 Jul 1;12:1783-1794. doi: 10.2147/IDR.S203238. eCollection 2019.
7
Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.来自中国北方某单一机构的人类艰难梭菌分离株的分子流行病学及抗菌药物敏感性
Medicine (Baltimore). 2018 Jun;97(25):e11219. doi: 10.1097/MD.0000000000011219.
8
Genomic survey of Clostridium difficile reservoirs in the East of England implicates environmental contamination of wastewater treatment plants by clinical lineages.英格兰东部艰难梭菌储库的基因组调查提示临床株系污染了废水处理厂的环境。
Microb Genom. 2018 Mar;4(3). doi: 10.1099/mgen.0.000162. Epub 2018 Mar 2.
9
Comparative genome and phenotypic analysis of three Clostridioides difficile strains isolated from a single patient provide insight into multiple infection of C. difficile.对从单一患者中分离出的三株艰难梭菌的比较基因组和表型分析为艰难梭菌的多次感染提供了深入了解。
BMC Genomics. 2018 Jan 2;19(1):1. doi: 10.1186/s12864-017-4368-0.
10
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.开发一种含二元毒素的新型疫苗，用于预防艰难梭菌疾病，对NAP1菌株具有更高疗效。
PLoS One. 2017 Jan 26;12(1):e0170640. doi: 10.1371/journal.pone.0170640. eCollection 2017.

本文引用的文献

1
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.与毒素A阴性、毒素B阳性艰难梭菌gyrB基因新突变相关的对莫西沙星和加替沙星的高水平耐药性。
J Antimicrob Chemother. 2006 Dec;58(6):1264-7. doi: 10.1093/jac/dkl398. Epub 2006 Oct 3.
2
Emergence of Clostridium difficile-associated disease in North America and Europe.北美和欧洲艰难梭菌相关疾病的出现。
Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18. doi: 10.1111/j.1469-0691.2006.01580.x.
3
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.一种新出现的艰难梭菌菌株产生毒素，该菌株与北美和欧洲的严重疾病暴发有关。
Lancet. 2005;366(9491):1079-84. doi: 10.1016/S0140-6736(05)67420-X.
4
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem.克林霉素、头孢菌素、氟喹诺酮类药物与艰难梭菌相关性腹泻：这是一个抗菌药物耐药性问题。
Clin Infect Dis. 2004 Mar 1;38(5):646-8. doi: 10.1086/382084. Epub 2004 Feb 11.
5
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.gyrA和gyrB突变与艰难梭菌对环丙沙星和莫西沙星的交叉耐药性有关。
Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. doi: 10.1128/AAC.46.11.3418-3421.2002.
6
Clostridium difficile.艰难梭菌
Gastroenterol Clin North Am. 2001 Sep;30(3):753-77, ix-x. doi: 10.1016/s0889-8553(05)70209-0.
7
Mechanisms of fluoroquinolone resistance.氟喹诺酮耐药机制。
Drug Resist Updat. 1999 Feb;2(1):38-55. doi: 10.1054/drup.1998.0068.
8
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.产毒艰难梭菌分离株对莫西沙星的耐药性与gyrA基因突变有关。
Antimicrob Agents Chemother. 2001 Aug;45(8):2348-53. doi: 10.1128/AAC.45.8.2348-2353.2001.
9
In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.新一代氟喹诺酮类药物对基因分型不同及难以区分的艰难梭菌分离株的体外活性
J Antimicrob Chemother. 2000 Oct;46(4):551-6. doi: 10.1093/jac/46.4.551.
10
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.四家医院中由耐克林霉素艰难梭菌菌株引起的腹泻流行。
N Engl J Med. 1999 Nov 25;341(22):1645-51. doi: 10.1056/NEJM199911253412203.

gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.

作者信息

Drudy Denise, Kyne Lorraine, O'Mahony Rebecca, Fanning Séamus

出版信息

Emerg Infect Dis. 2007 Mar;13(3):504-5. doi: 10.3201/eid1303.060771.

DOI:10.3201/eid1303.060771
PMID:17552115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2725882/
Abstract
摘要